Significant advances in treatment for chronic spontaneous urticaria (CSU), hereditary angioedema (HAE), and anaphylaxis were presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) and are discussed by Dr Ruchi Gupta of Northwestern University.
Dr Gupta begins by highlighting a phase 3 trial of dupilumab; previously approved in atopic dermatitis and asthma, this biologic now shows promise in CSU.
Another emerging therapy is remibrutinib, a Bruton's tyrosine kinase inhibitor that showed efficacy in controlling CSU symptoms in two phase 3 trials. Dr Gupta suggests remibrutinib, as an oral therapy, may offer an important alternative to omalizumab and dupilumab, which are injectable agents.
Next, Dr Gupta turns to HAE and a phase 3 study of donidalorsen that showed improved disease control and reduced HAE attacks compared to three existing treatments.
She then discusses a trial of sebetralstat, specifically in laryngeal HAE. Sebetralstat provided rapid symptom relief in a condition often constituting a medical emergency.
Finally, she highlights one study among many at AAAAI focusing on new delivery systems for epinephrine, the first-line treatment for anaphylaxis. A phase 3 study compared the pharmacokinetic profile of patients taking sublingual epinephrine to those who used autoinjectors or manual intramuscular injections. Sublingual administration provided comparable efficacy and rapid relief.